Key result
Higher omega-3 levels linked to ~32% lower odds of telomere shortening per SD.
Cohort (n=608)
Answers are grounded in this paper and cite their sources.
Prospective cohort study shows slower telomere shortening with higher marine omega-3 fatty acid levels in patients with coronary artery disease, suggesting a potential cellular anti-aging pathway.
CONTEXT: Increased dietary intake of marine omega-3 fatty acids is associated with prolonged survival in patients with coronary heart disease. However, the mechanisms underlying this protective effect are poorly understood. OBJECTIVE: To investigate the association of omega-3 fatty acid blood levels with temporal changes in telomere length, an emerging marker of biological age. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study of 608 ambulatory outpatients in California with stable coronary artery disease recruited from the Heart and Soul Study between September 2000 and December 2002 and followed up to January 2009 (median, 6.0 years; range, 5.0-8.1 years). MAIN OUTCOME MEASURES: We measured leukocyte telomere length at baseline and again after 5 years of follow-up. Multivariable linear and logistic regression models were used to investigate the association of baseline levels of omega-3 fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) with subsequent change in telomere length. RESULTS: Individuals in the lowest quartile of DHA+EPA experienced the fastest rate of telomere shortening (0.13 telomere-to-single-copy gene ratio [T/S] units over 5 years; 95% confidence interval [CI], 0.09-0.17), whereas those in the highest quartile experienced the slowest rate of telomere shortening (0.05 T/S units over 5 years; 95% CI, 0.02-0.08; P < .001 for linear trend across quartiles). Levels of DHA+EPA were associated with less telomere shortening before (unadjusted beta coefficient x 10(-3) = 0.06; 95% CI, 0.02-0.10) and after (adjusted beta coefficient x 10(-3) = 0.05; 95% CI, 0.01-0.08) sequential adjustment for established risk factors and potential confounders. Each 1-SD increase in DHA+EPA levels was associated with a 32% reduction in the odds of telomere shortening (adjusted odds ratio, 0.68; 95% CI, 0.47-0.98). CONCLUSION: Among this cohort of patients with coronary artery disease, there was an inverse relationship between baseline blood levels of marine omega-3 fatty acids and the rate of telomere shortening over 5 years.
No takes yet. Share an insight, caveat, or question.
Ramin Farzaneh‐Far (2010) conducted a cohort in Stable coronary artery disease (n=608). Baseline blood levels of marine omega-3 fatty acids (DHA+EPA) vs. Lowest quartile of DHA+EPA (or per 1-SD decrease) was evaluated on Change in leukocyte telomere length (telomere shortening) over 5 years (OR 0.68, 95% CI 0.47-0.98, p=< .001). Higher baseline marine omega-3 fatty acid (DHA+EPA) levels were associated with slower 5-year telomere shortening.
Synapse has enriched 10 related papers. Consider them for comparative context: